Table 3.
Total (n = 62/202) | No-poly RRMS (n = 30/62) | Minor-poly RRMS (n = 8/62) | Major-poly RRMS (n = 24/62) | |
---|---|---|---|---|
Flu-like syndrome | 14 (22.6) | 9 (30) | 2 (25) | 3 (12.5) |
Gastrointestinal side effects | 14 (22.6) | 7 (23.4) | 1 (12.5) | 6 (25) |
Injection sites reactions | 4 (6.5) | 2 (6.6) | 1 (12.5) | 1 (4.2) |
Transaminases elevation | 9 (14.5) | 3 (10) | 2 (25) | 4 (16.7) |
Thrombocytopenia | 1 (1.6) | – | 1 (12.5) | – |
Lymphocytopenia | 2 (3.2) | – | 1 (12.5) | 1 (4.2) |
Dysthyroidism | 8 (12.9) | 5 (16.6) | – | 3 (12.5) |
Arrhythmia | 1 (1.6) | – | – | 1 (4.2) |
Depression | 9 (14.5) | 4 (13.4) | – | 5 (20.7) |
AE, adverse event; DMT, disease-modifying therapy; RRMS, relapsing–remitting multiple sclerosis.